OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI:10.1016/j.jtho.2024.09.061

T.J.N. Hiltermann , H. Izumi , B.C. Cho , S. Cunha , P. Danchaivijitr , E. Felip , G.F. Ho , K. Leventakos , Y. Li , S. Sugawara , P.J. Voon , E. Wauters , T.-Y. Yang , M. Brandão , H. Chen , I. Achour , S. Colebrook , K. Sone , N. Bhulani , D. Karanovic , Y. Wang

引用次数: 0

查看原文本刊更多论文

OA11.03 抗PD-1/TIGIT双特异性药物Rilvegostomig治疗PD-L1 1-49%或≥50%的CPI无效转移性NSCLC的有效性和安全性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.